This company has been acquired
Applied Genetic Technologies Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Wichtige Informationen
-39.8%
Wachstumsrate der Gewinne
-21.1%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | -57.4% |
| Eigenkapitalrendite | -398.0% |
| Netto-Marge | -21,610.5% |
| Letzte Ertragsaktualisierung | 30 Sep 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Aufschlüsselung der Einnahmen und Ausgaben
Wie Applied Genetic Technologies Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -70 | 17 | 28 |
| 30 Jun 22 | 0 | -69 | 17 | 28 |
| 31 Mar 22 | 1 | -63 | 17 | 25 |
| 31 Dec 21 | 1 | -63 | 16 | 23 |
| 30 Sep 21 | 1 | -60 | 15 | 22 |
| 30 Jun 21 | 1 | -58 | 15 | 21 |
| 31 Mar 21 | 0 | -60 | 14 | 21 |
| 31 Dec 20 | 0 | -57 | 14 | 21 |
| 30 Sep 20 | 2 | -50 | 14 | 27 |
| 30 Jun 20 | 2 | -46 | 14 | 21 |
| 31 Mar 20 | 3 | -42 | 13 | 21 |
| 31 Dec 19 | 24 | -19 | 13 | 29 |
| 30 Sep 19 | 28 | -15 | 13 | 20 |
| 30 Jun 19 | 42 | -2 | 13 | 19 |
| 31 Mar 19 | 47 | 2 | 13 | 2 |
| 31 Dec 18 | 29 | -18 | 14 | 1 |
| 30 Sep 18 | 28 | -19 | 14 | 5 |
| 30 Jun 18 | 24 | -21 | 14 | 0 |
| 31 Mar 18 | 27 | -18 | 14 | 27 |
| 31 Dec 17 | 32 | -11 | 13 | 15 |
| 30 Sep 17 | 38 | -4 | 12 | 15 |
| 30 Jun 17 | 39 | 0 | 11 | 15 |
| 31 Mar 17 | 43 | 6 | 11 | 11 |
| 31 Dec 16 | 47 | 10 | 10 | 11 |
| 30 Sep 16 | 48 | 11 | 10 | 11 |
| 30 Jun 16 | 47 | -1 | 10 | 11 |
| 31 Mar 16 | 36 | -12 | 10 | 0 |
| 31 Dec 15 | 24 | -20 | 11 | 0 |
Qualität der Erträge: AGTC is currently unprofitable.
Wachsende Gewinnspanne: AGTC is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.
Beschleunigtes Wachstum: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: AGTC has a negative Return on Equity (-398.02%), as it is currently unprofitable.